Search
Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.
Silicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Mixtures: Calcium Complex High GradeMedifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Aranidipine
go.drugbank.com/drugs/DB09229Experimental[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88]
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Pyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedPyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for nor...
Mixtures: High Potency Vitamin B Complex + C Tab, High Potency Multivitamins & Minerals CapletsDehydrocholic acid
go.drugbank.com/drugs/DB11622ApprovedThe use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies
SB 224289
go.drugbank.com/drugs/DB17052ExperimentalSB-224289 is a small molecule with a high affinity for human 5-HT1B receptors.[A253122]